Gyre Therapeutics (NASDAQ:GYRE) COO Weiguo Ye Sells 12,820 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) COO Weiguo Ye sold 12,820 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total value of $78,843.00. Following the completion of the transaction, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. This represents a 1.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Weiguo Ye also recently made the following trade(s):

• On Wednesday, May 20th, Weiguo Ye sold 9,400 shares of Gyre Therapeutics stock. The stock was sold at an average price of $6.15, for a total value of $57,810.00.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock opened at $6.06 on Friday. The firm has a market cap of $587.99 million, a P/E ratio of -67.33 and a beta of 2.03. The business’s fifty day moving average is $7.24 and its two-hundred day moving average is $7.60. Gyre Therapeutics, Inc. has a 52 week low of $5.97 and a 52 week high of $11.61.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The business had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%. On average, equities research analysts predict that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on GYRE shares. Wall Street Zen lowered Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research lowered Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Finally, Weiss Ratings lowered Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.00.

Institutional Investors Weigh In On Gyre Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in GYRE. Bank of America Corp DE raised its position in shares of Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after acquiring an additional 1,996 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Gyre Therapeutics by 28.6% during the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after acquiring an additional 89,390 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after acquiring an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after acquiring an additional 3,244 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new stake in shares of Gyre Therapeutics during the third quarter worth $38,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.